Ceribell adds two directors with device and health-system backgrounds
Ceribell has expanded its board of directors with the appointments of Thomas West and Sharon O'Keefe, bringing commercial medtech scaling experience and large health-system leadership to the Sunnyvale-based company as it pushes wider adoption of its point-of-care electroencephalography platform.
The company, which listed on Nasdaq under the ticker CBLL, says its EEG system is now deployed in more than 680 US hospitals. The platform combines portable hardware with AI-powered algorithms and carries FDA clearance for detecting seizure and delirium in intensive care units and emergency departments.
The appointments
West brings a track record of steering medical technology businesses through high-value exits. He served as president and chief executive of neurostimulation company Nalu Medical, which was acquired by Boston Scientific for $600 million in January 2026, and before that led Intersect ENT through its $1.1 billion acquisition by Medtronic in 2022. Earlier roles included Worldwide President of Diagnostic Solutions at Hologic and more than two decades at Johnson & Johnson, where he held divisional leadership positions across its LifeScan diabetes business. He currently sits on the boards of SI-BONE, Cyted Health and ViCentra.
West said Ceribell had "established a new category in point-of-care brain monitoring, supported by a growing body of clinical evidence and rapid user adoption," and expressed an intention to help the company expand further.
O'Keefe joins from a career at the apex of US academic medicine. Her most recent role was president of the University of Chicago Medical Center and chief operating officer of the wider University of Chicago Medicine health system, where she oversaw more than $2 billion in annual operating revenue. Previous positions included the presidency of Loyola University Medical Center and senior operating roles at Beth Israel Deaconess Medical Center and Barnes-Jewish Hospital. Modern Healthcare named her one of its 100 Most Influential People in Healthcare in 2013.
O'Keefe described growing health-system demand for "high-value tools that support timely, accurate decisions at the bedside" and said Ceribell's platform aligned with that priority.
Market context
Point-of-care neurological monitoring occupies a relatively nascent but expanding corner of the broader medical devices market. Traditional EEG has historically required specialist neurophysiology staff and fixed equipment, creating a gap in acute-care settings where rapid seizure detection carries significant clinical consequence. Ceribell positions its system as addressing that gap directly, and the presence of AI-assisted interpretation is a differentiating feature that several other digital-health and medtech companies are also pursuing in adjacent diagnostic categories.
The board additions suggest Ceribell is preparing for a phase of commercial acceleration. West's experience navigating two sizeable M&A outcomes gives the company access to perspective on strategic partnerships and exit pathways, while O'Keefe's operational background in large health systems is directly relevant to negotiating enterprise-level procurement and integration agreements. The combination of both profiles in a single board expansion is a deliberate signal to institutional investors that management is thinking ahead to scale, not just to product development.
Ceribell did not announce any changes to its executive leadership team alongside the board news, and gave no updated guidance on revenue or deployment targets.